CV Therapeutics Reports 2007 Fourth Quarter and Full Year Financi...( Loss from operations (33378) ...)

Loss from operations (33,378) (69,625) (180,867) (278,485)

Other income (expense), net:

Interest and other

income, net 2,421 4,731 12,533 16,832

Interest expense (3,174) (3,166) (12,672) (12,667)

Total other income

(expense), net (753) 1,565 (139) 4,165

Net loss $(34,131) $(68,060) $(181,006) $(274,320)

Basic and diluted net

loss per share $(0.57) $(1.18) $(3.05) $(5.49)

Shares used in computing

basic and diluted net

loss per share 59,696 57,823 59,335 49,983

(1) Costs and expenses include non-recurring stock-based compensation

expense related to the acceleration of stock options and the voluntary

forfeiture of stock appreciation rights as follows:

Cost of sales $- $- $109 $-

Research and development - - 4,606 -

Selling, general and

administrative - - 8,471 -

Total non-recurring

stock-based compensation

charges $- $- $13,186 $-

Reconciliation of GAAP Items to Non-GAAP Items (2):

Net loss, as reported $(34,131) $(68,060) $(181,006) $(274,320)

Adjustments:

Non-recurring stock-based

compensation charges - - 13,186 -

Restructuring charges (11) - 6,763 -

Net loss, non-GAAP $(34,142) $(68,060) $(161,057) $(274,320)

Basic and diluted net

loss per share,

as reported $(0.57) $(1.18) $(3.05) $(5.49)

Adjustments $0.00 $- $0.34
'/>"/>